Form 4: Rapport Therapeutics' Chief Scientific Officer Sells Shares Under 10b5-1 Trading Plan

David Bredt, Chief Scientific Officer of Rapport Therapeutics, sold 8,500 shares of common stock on April 15, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• David Bredt, the Chief Scientific Officer of Rapport Therapeutics, sold 8,500 shares of common stock on April 15, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 12, 2024.
• The shares were sold at a weighted average price of $9.5659, with individual transaction prices ranging from $9.18 to $10.03.
• Following the transaction, Bredt directly owns 460,642 shares of Rapport Therapeutics.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price upon request.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale by a key executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Rapport Therapeutics, David Bredt, Chief Scientific Officer, stock sale, Form 4, Rule 10b5-1, insider trading, securities, RAPP